Clinical Trial Update: 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial update for a CAR T cell therapy (19(T2)28z1xx) in various B-cell cancers. The study is sponsored by Memorial Sloan Kettering Ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Indolent Non-hodgkin Lymphoma
• Marginal Zone Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed Follicular Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• 19(T2)28z1xx CAR T cells

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING